Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Los Angeles, California--(Newsfile Corp. - September 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Annovis Bio, Inc. ("Annovis" or "the Company") (NYSE American: ANVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2021 and July 28, 2021,...

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Annovis Bio, Inc..

ANVS CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.

BlueCity Holdings Limited

View

NEW YORK, NY / ACCESSWIRE / September 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLCT, ANVS and VIEW

Kanzhun Ltd

Royal Philips

NEW YORK, NY / ACCESSWIRE / September 5, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: BZ PHG ANVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS

Live Ventures

Stable Road Acquisition Corp

NEW YORK, NY / ACCESSWIRE / September 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for SRAC, LIVE and ANVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Berwyn, Pennsylvania--(Newsfile Corp. - September 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS), today announced that an interview with CEO and President Dr. Maria Maccecchini, Ph.D. will air on The RedChip Money Report on Bloomberg US on this Saturday September 4th at 7 p.m. Eastern Time. Bloomberg TV is available in an estimated...

Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

On Aug 31, ACIU reported mixed p2 Alzheimer's Disease (AD) trial data. While comparing ACIU and ANVS' AD trial data, some ANVS investors on Stocktwits forum seem unclear about ANVS' p2a data.

Annovis Bio's Latest P2a Alzheimer's Biomarkers Presentation Leaves Investors Confused

Piedmont Lithium

NEW YORK, NY / ACCESSWIRE / September 1, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PLL, PHG and ANVS

New York, New York--(Newsfile Corp. - August 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"), of the important October 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Annovis Bio securities during the Class Period you may be entitled to compensation without payment of any out of...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action - ANVS

ATI Physical Therapy

Activision Blizzard

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for ATVI, ANVS and ATIP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Churchill Capital Corp IV

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCIV, ANVS and ATIP

James River Group Holdings

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JRVR, ATVI and ANVS

RADNOR, Pa.--(BUSINESS WIRE)---- $ANVS--Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Shareholders of Securities Fraud Class Action Lawsuit

ANVS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Shareholders of Securities Fraud Class Action Lawsuit

RADNOR, Pa., Aug. 27, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021 , inclusive (the "Class Period").

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.

New York, New York--(Newsfile Corp. - August 27, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...

ANVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

San Diego, California--(Newsfile Corp. - August 27, 2021) - Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE American: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"), have until October 18, 2021 to seek appointment as lead plaintiff in the Annovis Bio class action lawsuit. The Annovis Bio class action lawsuit (Zhou v. Annovis Bio, Inc., No. 21-cv-03668) charges Annovis Bio and...

DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit - ANVS

Sesen Bio Inc.

Zymergen

NEW YORK, NY / ACCESSWIRE / August 27, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZY, ANVS and SESN

New Orleans, Louisiana--(Newsfile Corp. - August 26, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until October 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Annovis Bio, Inc. (NYSE: ANVS), if they purchased the Company's securities between May 21, 2021 and July 28, 2021, inclusive (the...

ANNOVIS BIO INVESTOR NOTICE BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Shareholders of Lead Plaintiff Deadline in Class Action Lawsuit Against Annovis Bio, Inc. - ANVS

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE American: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Annovis Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS

Cassava Sciences Inc

It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.

Better Biotech Stock: Cassava Sciences vs. Annovis Bio

SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"), have until October 18, 2021 to seek appointment as lead plaintiff in the Annovis Bio class action lawsuit.  The Annovis Bio class action lawsuit (Zhou v.

ANVS NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/anvs. This class action seeks

ANVS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

Presentation will highlight positive biomarker data that corroborates the positive efficacy data from two Phase 2 studies of ANVS401Dr. Maccecchini to present virtually, Thursday, August 26, at 1:00 p.m. ETBerwyn, Pennsylvania--(Newsfile Corp. - August 25, 2021) - Annovis, Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, announced today that Maria Maccecchini, PhD, Founder, CEO and President of Annovis Bio, will present at...

Annovis Bio to Present at Biomarkers for Alzheimer's Disease Summit 2021

AdaptHealth Corp

NEW YORK, NY / ACCESSWIRE / August 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

News for Annovis Bio Stock (ANVS)